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Autism is a neurodevelopmental disorder characterized by problems in communication, social skills, and repetitive behavior.
Recent studies suggest that apoptotic and inﬂammatory mechanisms may contribute to the pathogenesis of this disorder. Nuclear
factor-κB(NF -κB)isanimportantgenetranscriptionalfactorinvolvedinthemediationofinﬂammationandapoptosis.Thisstudy
examined the activities of the NF-κB signaling pathway in the brain of autistic subjects and their age-matched controls. The NF-κB
activation is also determined in the brain of BTBR mice, which is a promising animal model for study of pathogenic mechanisms
responsible for autism. Our results showed that the level of IKKα kinase, which phosphorylates the inhibitory subunit IκBα,i s
signiﬁcantly increased in the cerebellum of autistic subjects. However, the expression and phosphorylation of IκBα are not altered.
In addition, our results demonstrated that the expression of NF-κB (p65), and the phosphorylation/activation of NF-κB (p65) at
Ser536 are not signiﬁcantly changed in the cerebellum and cortex of both autistic subjects and BTBR mice. Our ﬁndings suggest
that the NF-κB signaling pathway is not disregulated in the brain of autistic subjects and thus may not be signiﬁcantly involved in
the processes of abnormal inﬂammatory responses suggested in autistic brain.
1.Introduction
Autismisasevereneurodevelopmentaldisorderofchildhood
characterizedbyimpairmentsinsocialinteraction,deﬁcitsin
verbal and nonverbal communication, and restricted, repet-
itive, and stereotypical patterns of behavior and interests
(DSMIV criteria, American Psychiatric Association, 1994).
Many areas of the brain in autism show abnormalities that
include decreased Purkinje cell counts in cerebellar hemi-
spheres and vermis [1], loss of granular cells [2], and
Purkinje cell atrophy [3, 4]. Susceptibility to autism is clearly
attributable to genetic factors [5, 6], but the etiology of
this disorder is unknown, and no biomarkers have yet been
proven to be characteristic of autism.
The BTBR T+tfJ( B T B R )m i c eh a v eb e e ns u g g e s t e dt ob e
a useful animal model for autism studies since they demon-
stratelowlevelsofsociabilitycomparedtotheC57BL/6J(B6)
mice [7–10]. The BTBR mice also exhibit an unusual pattern
of ultrasonic vocalizations and high levels of self-grooming
[9, 11–13] that may be homologous to the communication
deﬁcits and repetitive behaviors observed in autism. Thus,
the BTBR strain of mice is currently a promising model for
understanding the mechanisms that could be responsible for
the pathogenesis of autism.
Recently, emerging evidence points to central nervous
system (CNS) inﬂammatory and apoptotic mechanisms
being responsible for certain neuropsychiatric disorders
including autism. Several inﬂammatory cytokines including
tumor-necrosis-factor- (TNF-) α, interferon- (IFN-) γ,I L -
1β,I L - 6 ,a n dI L - 8a r ef o u n dt ob ee l e v a t e di nt h eb r a i n ,
serum, plasma, and cerebrospinal ﬂuid (CSF) of autistic
subjects [14–22]. In addition, previous studies, including
ours, have found that the antiapoptotic Bcl2 protein is
decreased, while the proapoptotic p53 protein is increased in
theautisticbrain[22,23].WealsofoundthattheBDNF-Akt-
Bcl2 anti-apoptosis pathway is compromised in the frontal
cortex of autistic subjects [22]. The BDNF-PI3K/Akt-Bcl2
signaling pathway plays an important role in inhibiting
apoptosis and promoting neuronal survival.2 Mediators of Inﬂammation
Table 1: Study subject information.
Case Age Sex Group PMI (h) Seizure Retardation Medication Cause of death
17 M C o n t r o l 1 2 −− Concerta, Clonidine Drowning
28 M C o n t r o l 3 6 −− − Drowning
34 F C o n t r o l 2 1 −− − Lymphocytic myocarditis
49 F C o n t r o l 2 0 −− Albuterol, Zyrtec Asthma
56 M C o n t r o l 1 8 −− − Multiple injuries
6 14 M Control 16 −− − Cardiac Arrhythmia
7 11 F Control 12 −− − Asthma
8 7 M Autism 20 −− − Drowning
9 8 M Autism 16 −− − Drowning
10 4 F Autism 13 −− − Multiple injuries
11 9 F Autism 24 −− − Smoke inhalation
12 8 M Autism 12 − + − Drowning
13 14 M Autism 12 + + − Drowning
14 7 M Autism 3 −− − Cancer
Nuclear factor-κB( N F - κB) is an important gene tran-
scriptional factor that mediates cellular responses in inﬂam-
mation, immunity, development, cell proliferation and
apoptosis [24–30]. The inactive form of NF-κBi sl o c a l i z e d
to the cytoplasm and consists of DNA-binding p50 and
p65 subunits and an inhibitory subunit, designated IκBα
[31]. Activation occurs via phosphorylation of IκBα at Ser32
and Ser36, resulting in the ubiquitin-mediated proteasome-
dependent degradation of IκBα and the release and nuclear
translocation of active NF-κB dimmers [31]. The key reg-
ulatory step in this pathway involves activation of a high-
molecular-weight IKappaB kinase (IKK) complex, consisting
of three tightly associated IKK subunits. IKKα and IKKβ
serve as the catalytic subunits of the kinase. A large number
of genes involved in cellular proliferation, apoptosis, and
inﬂammation,areregulateduponactivationofNF-κB.These
genes include antiapoptotic genes (Bcl2 and Bcl-xl), cell
cycle-regulatory genes (cyclin D1), genes encoding adhesion
molecules, chemokines, inﬂammatory cytokines, and genes
involved in tumor metastases [26–28, 30, 32].
NF-κB signaling pathway regulates gene transcription
of Bcl2. NF-κB is also an important transcriptional factor
for cytokines. Activation of NF-κB can be stimulated by
TNFα [33]. TNFα induces NF-κB p65 polyubiquitination
a n dd e g r a d a t i o n ,a sw e l la st e r m i n a t i o no fT N F α-mediated
NF-κBa c t i v a t i o n[ 34]. Although previous studies have
shown that the BDNF-Akt-Bcl2 antiapoptotic pathway is
downregulated and inﬂammatory cytokines are increased in
autistic brain [22, 35], whether the NF-κB signaling pathway
is altered in the autistic brain has not yet been investigated.
In the current study, we examined the entire NF-κB signaling
pathwayinthecerebellumof7autisticsubjectsandtheirage-
matched normal controls. We also determined the activity of
NF-κB in the frontal cortex of 6 autistic subjects and 6 BTBR
mice in comparison with the controls. Our results show
that the expression of IKKα, the kinase phosphorylating
the inhibitory subunit IκBα, is signiﬁcantly increased in the
cerebellum of autistic subjects as compared to age-matched
controls. We failed to detect the IKKβ expression in our
samples by western blot Assay and reckon it is because the
expression level of IKKβ is very low. However, the expression
and phosphorylation level of IκBα, which is the downstream
target of IKKα and IKKβ, are not signiﬁcantly changed in the
autistic cerebellum. In addition, our results showed that the
phosphorylation/activation of NF-κB (p65) at Ser536 is not
signiﬁcantly altered in the cerebellum and frontal cortex of
both autistic subjects and BTBR mice, as compared with the
controls. These results suggest that NF-κB signaling pathway
is not deregulated in the brain of autistic subjects and BTBR
mice.
2.SubjectsandMethods
2.1. Study Subjects. Frozen human brain tissue of seven
autistic subjects (mean age 8.1 ± 2.6 years) and seven
age-matched normal subjects (mean age 8.4 ± 2.3 years)
was obtained from the NICHD Brain and Tissue Bank
for Developmental Disorders. Donors with autism ﬁt the
diagnostic criteria of the Diagnostic and Statistical Manual-
IV, as conﬁrmed by the Autism Diagnostic Interview-
Revised. Participants were excluded from the study if they
had a diagnosis of fragile X syndrome, epileptic seizures,
obsessive-compulsive disorder, aﬀective disorders, or any
additional psychiatric or neurological diagnoses. The sub-
jects’ information is summarized in Table 1.
Six female BTBR T+tfJ (BTBR) and six B6 mice were
obtained from Jackson Laboratories (Bar Harbor, Me). Mice
were housed for 24 hours with ad lib food and water to ease
the stress before sacriﬁce. All procedures were conducted in
compliance with the NIH Guidelines for the Care and Use of
Laboratory Animals.
2.2. Preparation of Brain Tissue Homogenate. Frozen cerebel-
lum and frontal cortex tissues from human and mice were
homogenized (10% W/V) in cold buﬀer containing 50mM
Tris-HCl (pH 7.4), 8.5% sucrose, 2mM EDTA, 10mM
β-mercaptoethanol, and protease inhibitors cocktail (Sigma-
Aldrich). The protein concentration was assayed by the BCA
method [36, 37].Mediators of Inﬂammation 3
2.3. Western Blot Analysis. Antibodies IKKα,I K K β,I k B α,
NF-κB (p50/52), NF-κB (p65), and phospho-NF-kB (p65)
were obtained from commercial sources (Cell Signal-
ing Technology, USA). For western blot analysis, brain
homogenate samples in SDS sample buﬀer (20% glycerol,
100mM Tris, pH 6.8, 0.05% w/v Bromophenol blue, 2.5%
SDS (w/v), and 250mM DTT) were denatured by heating
at 100◦C for three minutes. Forty to eighty micrograms of
protein per lane per subject was loaded onto a 12% acryl-
bisacrylamide gel and electrophoresed for 2h at 120V at
room temperature (RT). The proteins were electroblotted
onto a nitrocellulose membrane for 1h at 100V at 4◦C.
Protein blots were then blocked with 5% milk in phosphate
buﬀeredsaline(PBS)with1%Tween(PBST).Afterblocking,
the blots were incubated with primary antibody overnight
at 4◦C( a n t i - I K K α 1:1000; anti-IKKβ 1:500; anti-IκBα
1:1000; anti-NF-κB (p50/52) 1:500; anti-NF-κB p65 1:500;
anti-phospho-NF-κB p65 1:500) followed by a secondary
antibody incubation for 1h at RT (goat anti-mouse IgG
or goat anti-rabbit IgG, HRP conjugated, 1:5000, Sigma).
After three washes in PBST (each time for 10 minutes),
the blots were visualized using the ECL detection system
(Amersham Pharmacia Biotech) and exposed to Hyper ﬁlm
ECL (Amersham Pharmacia Biotech). Sample densities were
analyzed blind to the diagnosis, using Image J software. The
densities of IKKα,I κBα,a n dN F - κB p65 expression bands,
as well as the β-actin expression bands, were quantiﬁed with
background subtraction. Statistical analyses were conducted
using unpaired t-tests with signiﬁcance established at P<
0.05.
2.4. Immunohistochemistry. The immunohistochemistry
studies were carried out on cerebellar cortex, which is the
thin gray surface layer of the cerebellum, consisting of an
outer molecular layer, a single layer of purkinje cells, and
an inner granular layer. Six μmp a r a ﬃn sections from 10%
formalin-ﬁxed cerebellum specimens of autistic subjects
and the age-matched controls were deparaﬃnized with
Xylene (2X) and ethanol of 100% (2X), 80%, 50%, and 25%
concentration and washed in TBS, 5 minutes each time. The
sections were then incubated with IκBα antibody (1:200)
and NF-κB p65 antibody (1:150) overnight in a moisture
chamber at 4◦C. After washing in 0.1M PBS for 5 minutes,
the sections were further incubated with secondary antibody
(biotinylated horse anti-mouse IgG or biotinylated horse
anti-rabbit IgG, VectaStain Elite ABC Kit, Vector Lab) for 30
minutes at RT, followed by incubation in Avidin-biotinylated
peroxidase (VectaStain Elite ABC Kit) for 45 minutes at RT
and in 0.0125g DAB/25mL 0.05M TBS/1 drop 30% H2O2
for 10 minutes at RT. All sections were washed in sequence
with TBS, 25%, 50%, 80%, and 100% ethanol (2X), and
Xylene (2X) before mounting for view under the microscope
(Zeiss, West Germany).
2.5. Enzyme-Linked Immunosorbent Assay (ELISA). Ah u -
man phospho-NF-κB p65 (Ser 536) Sandwich ELISA kit
and a human phospho-IκBα (Ser 32) Sandwich ELISA
kit (Cell Signaling Technology, USA) were used, according
to the protocol of the company, to measure the concen-
tration of phospho-NF-κB (p65) and phospho-IκBα in
the homogenates of cerebellum. 100μL of each standard
and sample in duplicate added into appropriate wells in a
96-well microplate coated with anti-human phospho-NF-
κB (p65) and anti-human phospho-IκBα,r e s p e c t i v e l y ,a n d
incubated overnight at 4◦C. The plates were washed 4 times
with 1x Wash Solution (200μL each) and incubated with
100μL detection antibody for 1 hour at 37◦C. Afterwards,
the plates were washed 4 times with 1x Wash Solution
(200μL each) and incubated with 100μL of HRP-linked
secondary antibody for 30 minutes at 37◦Cf o l l o w e db ya
further 5 times wash and incubation with 100μLo fT M B
Substrate for 10 minutes at 37◦C in the dark. 100μLo fS t o p
Solution was added to each well, and the plates were read
within30minutesat450nmusingKineticMicroplateReader
(Molecular Devices). The average OD 450 of duplicate wells
was plotted against the dilution factor for each test specimen
on the same graph.
2.6. Statistical Analysis. We analyzed the statistical signif-
icance among groups with the unpaired t-test using the
StatView 5.0 software (SAS Institute, Inc.). The samples
shown in our study were all of the samples analyzed. All
data is presented as means ± SE. Signiﬁcance was accepted
at P<0.05 or better.
3. Results
3.1. IKKα Protein Expression Is Increased in the Cerebellum
of Autistic Subjects. western blot studies were conducted
to examine IKKα expression in the cerebellum of autistic
subjects and their age-matched controls. The results are
shown in Figure 1. The bands representing the 85kDa IKKα
protein expression in the cerebellum were stronger in the
autistic group than those in the control group (Figure 1(a)).
Quantitative analysis showed that the mean value of IKKα
expression was increased by 35% in the autistic subjects as
compared with the control subjects (P<0.05, Figure 1(b)).
We failed to detect IKKβ protein expression in the same
set of samples, possibly due to very low expression in the
cerebellum.
3.2. The Protein Expression and Phosphorylation of IκBα
Inhibitory Subunit in the Cerebellum of Autistic Subjects. To
examine the expression of the IκBα protein and the down-
stream target of IKKα and IKKβ, we carried out western
blot studies on the cerebellum of autistic subjects and their
age-matched controls. The results showed that there was
no signiﬁcant diﬀerence in IκBα protein expression between
the two groups (Figures 2(a) and 2(b)). To conﬁrm this
result, we examined IκBα protein expression in both autistic
cerebellum and the controls employing immunohistochem-
istry. Consistently, we detected no signiﬁcant diﬀerence in
IκBα protein expression in the two groups (Figure 2(c)). To
further determine the activities of IκBα, we then examined
the phosphorylation of IκBα (on Ser 32) in the same set
of samples using an ELISA approach and found that IκBα
phosphorylation was increased by 8.1% ± 1.9% in the4 Mediators of Inﬂammation
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Figure1:IKKαproteinexpressioninthecerebellumofautisticsubjects.(a)Twoindependentwesternblotstudiesoncerebellarhomogenates
using IKKα antibody (dilution 1:1000). Lanes 1–4 and 9–11 represent autistic subjects, and lanes 5–8 and 12–14 represent controls. The
lower panel shows actin bands (MW: 48kd), and the upper panel shows the IKKα bands (MW: 85kd). (b) The blots shown in (a) were
quantitated after being normalized by actin. Data are shown as mean ± SE.
∗P < 0.05 versus control group. White bars represent controls,
and black bars represent autistic subjects.
autistic cerebellum samples, but not signiﬁcant as compared
with the age-matched controls (P = 0.36, Figure 2(d)).
3.3. NF-κB (p65) Protein Expression in the Cerebellum of
Autistic Subjects. The increased expression of IKKα kinase
could result in an increased NF-κB activity. To test this
assumption, we examined the two subunits of NF-κB( N F -
κBp 6 5a n dN F - κB p50/52) in the cerebellum of the autistic
subjects and their age-matched controls. We did not detect
the expression of the NF-κB p50/52 subunit and assume it is
because the expression of NF-κB p50/52 in the cerebellum
is too low to be detected using western blot analysis. We
successfully detected the expression of NF-κB p65 (65kDa)
andfoundthatthebandswereslightlystrongerintheautistic
cerebellum than those in the control group (Figure 3(a)).
However, quantitative analysis showed no signiﬁcant diﬀer-
ence in NF-κB p65 expression between the autistic and the
control subjects (P>0.05, Figure 3(b)). This result was
further conﬁrmed by immunohistochemical studies using
the NF-κB p65 antibody. The positive immunoreaction was
similar in both the autistic cerebellum and the controls
(Figure 3(c)).
3.4. NF-κB (p65) Activities in the Cerebellum and Frontal
Cortex of Autistic Subjects. To further examine the activity
levels of NF-κB(p65) in the brain of autistic subjects, we
examined NF-κB(p65) phosphorylation (on Ser 536) in the
cerebellum and frontal cortex of autistic subjects and the
controls with an ELISA assay. Our results showed the mean
valuesofNF-κB(p65)phosphorylationwerenotsigniﬁcantly
changed in the cerebellum (P = 0.966) and frontal cortex
(P = 0.535) of autistic subjects, as compared to controls
(Figures 4(a) and 4(b)).
3.5. NF-κB (p65) Activities in the Cerebellum and Frontal
Cortex of BTBR Mice. Since BTBR mice are currently a
promising model for understanding the mechanisms that
could be responsible for the pathogenesis of autism, we also
examined the activity levels of NF-κB(p65) in the cerebellum
and frontal cortex of BTBR mice and B6 mice (control) by
determining the NF-κB(p65) phosphorylation on Ser 536
with an ELISA assay. Our results showed the mean values of
NF-κB(p65)phosphorylationwerenotsigniﬁcantlychanged
in the cerebellum (P = 0.136) and frontal cortex (P = 0.968)
of BTBR mice, as compared to the control B6 mice (Figures
5(a) and 5(b)).
4. Discussion
Emerging evidence suggests that apoptotic and inﬂamma-
tory mechanisms may be related to the pathogenesis of
autism. A number of studies have shown that apoptosis-
related proteins (p53, Bcl2) and several inﬂammatory
cytokines are altered in autistic brain [3, 4, 18–21]. NF-κB
is an important transcription factor that regulates cellular
responses in inﬂammation and apoptosis. A large number
of genes including the apoptosis-related Bcl2 and Bcl-xl,
and inﬂammation-related cytokines, can be regulated upon
activation of NF-κB (see illustration of the NF-κB signaling
pathway in Figure 6). To further investigate the mechanisms
that underlie the apoptotic and inﬂammatory changes in the
autistic brain, we examined the activity of the transcriptionalMediators of Inﬂammation 5
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Figure 2: IκBα inhibitory subunit expression in the cerebellum of autistic subjects. (a) Two independent western blot studies on cerebellar
homogenates using IκBα antibody (dilution 1:1000). Lanes 1–4 and 9–11 represent the controls, and lanes 5–8 and 12–14 represent the
autistic subjects. The upper panel shows actin bands (MW: 48kd), and the lower panel shows the IκBα bands (MW: 35kd). (b) Quantitative
analysis after being normalized by actin. Data are shown as mean ± SE. White bars represent controls, and black bars represent autistic
subjects. (c) Immunostaining of cerebellar sections using IκBα antibody (dilution 1:200). The expression of IκBα shown as very faint red
color was detected in the neural cells (indicated by arrows) in autistic cerebellum (right panel), as well as in the matched controls (left
panel). The image is viewed under high power microscopy. (d) Measurement of phospho-IκBα in the cerebellum of 7 autistic subjects and
the age-matched controls with ELISA. P = 0.36.
factor NF-κB in the cerebellum and frontal cortex of autistic
subjects and their age-matched controls. We also further
determined NF-κB activities in the cerebellum and frontal
cortex of BTBR mice that model autism. This is the ﬁrst
study to investigate how the NF-κB signaling pathway is
regulated in the autistic brain. Our results demonstrated
that the expression of IKKα was signiﬁcantly increased in
the autistic cerebellum as compared to the age-matched
normal controls. IKKα is a kinase upstream of the NF-κB
signaling pathway and phosphorylates two serine residues
located in the inhibitory subunit IκBα. This phosphorylation
event leads to IκBα release from the NF-κBc o m p l e xa n d
frees the NF-κB complex to enter the nucleus and activate
NF-κB-dependent gene expression [33, 38]. The increased
IKKα expression in the autistic brain implies a possible
increased IKKα kinase activity and a possible increased
phosphorylation of the inhibitory IκBα subunit. However,
by examining the expression of the IκBα subunit, as well
as the phosphorylation of IκBα in the cerebellum of 7
autistic subjects and their age-matched controls, we did6 Mediators of Inﬂammation
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Figure 3: NF-κB p65 protein expression in the cerebellum of autistic subjects. (a) Two independent western blot studies on cerebellar
homogenates using NF-κB p65 antibody (dilution 1:500). Lanes 1–4 and 9–11 represent the controls, and lanes 5–8 and 12–14 represent the
autistic subjects. The lower panel shows actin bands (MW: 48kd), and the upper panel shows the NF-κB p65 protein bands (MW: 65kd).
(b) The blots shown in (a) were quantitated after being normalized by actin. Data are shown as mean ± SE. White bars represent controls,
and black bars represent autistic subjects. (c) Immunostaining of cerebellar sections using NF-κB p65 antibody (dilution 1:150). Very faint
expression of NF-κB p65 (red color) was detected in the neural cells (indicated by arrows) in autistic cerebellar (right panel), as well as in the
matched controls (left panel). The image is viewed under high power microscopy.
not detect signiﬁcant diﬀerences in IκBα expression and
phosphorylation between the two groups.
To further determine the activity levels of NF-κB, we
utilized western blot, immunohistochemistry, and ELISA
approaches to examine the protein expression levels of both
the NF-κB p65 subunit and the NF-κB p50/52 subunit,
as well as the phosphorylation/activation levels of the
two subunits in the brain of autistic subjects and their
age-matched controls. Our results showed no signiﬁcant
diﬀerence in NF-κB p65 expression between the autistic
and the control subjects. The phosphorylation levels of NF-
κB p65 protein at Ser536 in the cerebellum and cortex of
autistic subjects are also not signiﬁcantly diﬀerent from that
o fc o n t r o ls u b j e c t s .T h eB T B Rs t r a i no fm i c ei sc u r r e n t l y
a promising model for understanding the mechanisms that
could be responsible for the pathogenesis of autism since
they demonstrate behaviors similar to autism. Thus, we also
examined the phosphorylation levels of NF-κB p65 protein
at Ser536 in the cerebellum and cortex of BTBR mice. We
foundnosigniﬁcantdiﬀerencesinthephosphorylationlevels
of NF-κB p65 protein at Ser536 in the cerebellum and cortex
of BTBR mice as compared with control B6 mice. All these
resultspointoutthattheactivityofNF-κBisnotdisregulated
in the autistic brain. We could not detect protein expression
of the NF-κB p50/52 subunit in the cerebellum of autistic
subjects or in control subjects. The very low expression levelMediators of Inﬂammation 7
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Figure 4:Phospho-NF-κBp65concentrationinthecerebellumand
cortex of autistic subjects. Measurement of phospho-NF-κBp 6 5i n
the cerebellum ((a) P = 0.966) and cortex ((b) P = 0.535) of six
autistic subjects and six age-matched controls with ELISA.
of this protein is the likely reason for its not being detectable
with the western blot method.
NF-κB p65 phosphorylation at Ser 536 regulates acti-
vation, nuclear localization, protein-protein interactions,
and transcriptional activities [39]. NF-κB p65 is a subunit
of the NF-κB transcriptional factor that actively regulates
expression of NF-κB-dependent genes involved in apoptosis
and inﬂammation. Antiapoptotic Bcl2 and Bcl-xl genes as
well as genes for cytokines have been shown to be regulated
through the activation of NF-κBp 6 5[ 24, 40–42]. On one
hand,constitutivelyexpressedNF-κBhasbeendemonstrated
to lead to resistance to cell death by diﬀerent inducers of
apoptosis and increased NF-κB activity has recently been
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Figure 5:Phospho-NF-κBp65concentrationinthecerebellumand
cortex of BTBR mice. Measurement of phospho-NF-κB p65 in the
cerebellum ((a) P = 0.136) and cortex ((b) P = 0.968) of six BTBR
mice and six age-matched control B6 mice with ELISA.
correlated with progression of diﬀerent cancers, especially
breast cancer, melanoma, and juvenile myelomonocytic
leukemia[43].Ontheotherhand,studieshavedemonstrated
that NF-κB is negatively regulated by antiapoptotic Bcl2
protein and speciﬁcally activated in the course of apoptosis
induced by serum withdrawal. This activation of NF-κBw a s
demonstrated to be necessary for the execution of the apop-
totic program [44]. These ﬁndings suggest a complicated
role of NF-κB signaling in the regulation of apoptosis and
inﬂammation.
Recently, a number of studies have suggested that apop-
tosis and inﬂammation in the central nerve system may be
associated with autism [3, 4, 18–22]. We and others have
found that the antiapoptotic factor Bcl2 is decreased in8 Mediators of Inﬂammation
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Figure 6: NF-κB signal transduction pathway. NF-κB heterodimer between p65 and p50/52 proteins is located in the cytosol complexed
with the inhibitory protein IκBα. Through the intermediacy of integral membrane receptors, a variety of extracellular signals (like TNFα or
growth factor BDNF) can activate the enzyme IκB kinase (IKK, consisting of Ikkα, β,a n dγ) via TAK1 or PI3K/Akt, respectively. IKK, in
turn, phosphorylates the IκBα protein, which results in dissociation of IκBα from NF-κB and eventual degradation by the proteosome. The
activated NF-κB is then translocated into the nucleus where it binds to speciﬁc sequences of DNA called response elements and initiates the
gene transcription.
the autistic brain [3, 22, 23] and the BDNF-Akt-Bcl2 anti-
apoptosis pathway is downregulated in the frontal cortex
of autistic subjects [35]. In addition, a number of studies
including ours found that the cytokines TNFα,I L - 6 ,G M -
CSF, IFN-γ, and IL-8 are signiﬁcantly elevated in the brain
andcerebrospinalﬂuid(CSF)ofautisticsubjects[18, 21, 22].
NF-κB was shown to be the transcriptional factor that
regulates the gene transcription of Bcl2 and inﬂammatory
cytokines such as TNFα [24, 29, 42, 44]. Go et al. [45]h a v e
also reported that valproic acid inhibits neural progenitor
cell death by activation of NF-κB signaling pathway, which
subsequently enhanced expression of antiapoptotic protein
Bcl-XL. We expected the NF-κB signaling activities altered in
the autistic brain. However, our studies demonstrated that
NF-κB signaling is not signiﬁcantly changed in autistic brain
as compared with normal controls. These results could be
explainedas(1)thealterationofinﬂammatorycytokinesand
apoptosis-related proteins in the autistic brain may not be
enough to stimulate or suppress the NF-κB activities and (2)
the consequence of dual role of NF-κB in the response to
inﬂammatory cytokines and apoptosis-related protein such
asBcl2.AnumberofstudieshavereportedthatNF-κBcanbe
activated in both transcriptionally activating and repressing
forms [38, 46]. This dual role of NF-κBh a sp r e s e n t e d
considerable complexities in understanding the mechanisms
of NF-κB action.
5. Conclusions
OurstudieshaveshownthatalthoughtheexpressionofIKKα
kinase, which is upstream of the NF-κB signaling pathway, is
signiﬁcantly increased in the cerebellum of autistic subjects
as compared with the age-matched controls, the phosphory-
lation/activation of the downstream IκBα inhibitory subunit
is not signiﬁcantly enhanced in the cerebellum of autistic
subjects. Our results further showed that both the expression
and phosphorylation of NF-κB p65 are not signiﬁcantly
altered in the cerebellum and cortex of autistic subjects as
compared with the control subjects. The phosphorylation
levels of NF-κB p65 are also not signiﬁcantly altered in the
cerebellum and cortex of BTBR mice that model autism.
These ﬁndings imply that NF-κB signaling pathway is not
disregulated in autism.Mediators of Inﬂammation 9
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